New York State Teachers Retirement System decreased its stake in Repligen Corp. (NASDAQ:RGEN) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 51,443 shares of the company’s stock after selling 3,900 shares during the period. New York State Teachers Retirement System’s holdings in Repligen Corp. were worth $1,407,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also made changes to their positions in RGEN. Virginia Retirement System purchased a new stake in shares of Repligen Corp. during the first quarter worth approximately $381,000. TIAA CREF Investment Management LLC boosted its stake in shares of Repligen Corp. by 26.3% in the first quarter. TIAA CREF Investment Management LLC now owns 203,734 shares of the company’s stock worth $5,464,000 after buying an additional 42,400 shares in the last quarter. BlackRock Group LTD boosted its stake in shares of Repligen Corp. by 6.3% in the first quarter. BlackRock Group LTD now owns 49,515 shares of the company’s stock worth $1,328,000 after buying an additional 2,915 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Repligen Corp. by 0.7% in the first quarter. BlackRock Fund Advisors now owns 2,457,356 shares of the company’s stock worth $65,906,000 after buying an additional 16,941 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Repligen Corp. by 2.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 875,808 shares of the company’s stock worth $23,489,000 after buying an additional 18,194 shares in the last quarter. Hedge funds and other institutional investors own 89.37% of the company’s stock.
Shares of Repligen Corp. (NASDAQ:RGEN) traded up 1.32% during trading on Tuesday, hitting $29.21. The stock had a trading volume of 246,833 shares. The stock’s 50-day moving average is $31.38 and its 200-day moving average is $28.07. The stock has a market cap of $986.89 million, a price-to-earnings ratio of 116.84 and a beta of 1.36. Repligen Corp. has a 12-month low of $20.07 and a 12-month high of $36.00.
Repligen Corp. (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.03. The business had revenue of $29.20 million for the quarter, compared to analysts’ expectations of $24.75 million. Repligen Corp. had a return on equity of 10.74% and a net margin of 8.69%. The company’s revenue for the quarter was up 35.8% compared to the same quarter last year. During the same period last year, the firm earned $0.11 earnings per share. On average, equities research analysts expect that Repligen Corp. will post $0.44 EPS for the current year.
Separately, Zacks Investment Research cut Repligen Corp. from a “hold” rating to a “sell” rating in a research report on Saturday, July 30th.
In other news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $32.58, for a total value of $87,966.00. Following the sale, the director now directly owns 9,394 shares in the company, valued at $306,056.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.30% of the stock is owned by insiders.
Repligen Corp. Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corp. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.